Vaccine-Associated Enhanced Viral Disease: Implications for Viral Vaccine Development.
Journal
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
ISSN: 1179-190X
Titre abrégé: BioDrugs
Pays: New Zealand
ID NLM: 9705305
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
accepted:
02
08
2021
pubmed:
10
9
2021
medline:
13
10
2021
entrez:
9
9
2021
Statut:
ppublish
Résumé
Vaccine-associated enhanced disease (VAED) is a serious barrier to attaining successful virus vaccines in human and veterinary medicine. VAED occurs as two different immunopathologies, antibody-dependent enhancement (ADE) and vaccine-associated hypersensitivity (VAH). ADE contributes to the pathology of disease caused by four dengue viruses (DENV) through control of the intensity of cellular infection. Products of virus-infected cells are toxic. A partially protective yellow fever chimeric tetravalent DENV vaccine sensitized seronegative children to ADE breakthrough infections. A live-attenuated tetravalent whole virus vaccine in phase III testing appears to avoid ADE by providing durable protection against the four DENV. VAH sensitization by viral vaccines occurred historically. Children given formalin-inactivated measles or respiratory syncytial virus (RSV) vaccines experienced severe disease during breakthrough infections. Tissue responses demonstrated that VAH not ADE caused these vaccine safety problems. Subsequently, measles was successfully and safely contained by a live-attenuated virus vaccine. The difficulty in formulating a safe and effective RSV vaccine is troublesome evidence that avoiding VAH is a major research challenge. VAH-like tissue responses were observed during breakthrough homologous virus infections in monkeys given severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS) vaccines.
Identifiants
pubmed: 34499320
doi: 10.1007/s40259-021-00495-6
pii: 10.1007/s40259-021-00495-6
pmc: PMC8427162
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Dengue Vaccines
0
Viral Envelope Proteins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
505-515Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Arvin AM, Fink K, Schmid MA, Cathcart A, Spreafico R, Havenar-Daughton C, et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature. 2020;584(7821):353–63.
Ricke DO. Two different antibody-dependent enhancement (ADE) risks for SARS-CoV-2 antibodies. Front Immunol. 2021;12:640093.
pubmed: 33717193
pmcid: 7943455
doi: 10.3389/fimmu.2021.640093
Fulginiti VA, Eller JJ, Downie AW, Kempe CH. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA. 1967;202(12):1075–80.
pubmed: 6072745
doi: 10.1001/jama.1967.03130250057008
pmcid: 6072745
Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol. 1969;89:449–63.
pubmed: 4305200
doi: 10.1093/oxfordjournals.aje.a120957
pmcid: 4305200
Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med. 2018;379(4):327–40.
pubmed: 29897841
doi: 10.1056/NEJMoa1800820
pmcid: 29897841
Halstead SB, Russell PK, Katzelnick LC, Markoff L, Aguiar M, Dans LR, et al. Ethics of a partially effective dengue vaccine: lessons from the Philippines. Vaccine. 2020;38(35):5572–6.
pubmed: 32654899
pmcid: 7347470
doi: 10.1016/j.vaccine.2020.06.079
Pedersen NC, Boyle JF. Immunologic phenomena in the effusive form of feline infectious peritonitis. Am J Vet Res. 1980;41:868–76.
Weiss RC, Scott FW. Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever. Comp Immune Microbiol Infect Dis. 1981;4:175–88.
doi: 10.1016/0147-9571(81)90003-5
Pedersen NC. An update on feline infectious peritonitis: diagnostics and therapeutics. Vet J. 2014;201(2):133–41.
pubmed: 24857253
pmcid: 7110619
doi: 10.1016/j.tvjl.2014.04.016
Ubol S, Halstead SB. How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin Vaccine Immunol. 2010;17(12):1829–35.
pubmed: 20876821
pmcid: 3008185
doi: 10.1128/CVI.00316-10
Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol. 2011;85(23):12201–15.
pubmed: 21937658
pmcid: 3209347
doi: 10.1128/JVI.06048-11
Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 2019;4(4):e123158.
Halstead SB, Katzelnick L. COVID-19 vaccines: should we fear ADE? J Infect Dis. 2020;222(12):1946–50.
pubmed: 32785649
doi: 10.1093/infdis/jiaa518
pmcid: 32785649
Halstead SB, Mahalingam S, Marovich MA, Ubol S, Mosser DM. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis. 2010;10(10):712–22.
pubmed: 20883967
pmcid: 3057165
doi: 10.1016/S1473-3099(10)70166-3
Boonnak K, Dambach KM, Donofrio GC, Marovich MA. Cell type specificity and host genetic polymorphisms influence antibody dependent enhancement of dengue virus infection. J Virol. 2011;85(4):1671–83.
pubmed: 21123382
doi: 10.1128/JVI.00220-10
pmcid: 21123382
Hawkes RA. Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls. Aust J Exp Biol Med Sci. 1964;42:465–82.
pubmed: 14202187
doi: 10.1038/icb.1964.44
pmcid: 14202187
Kliks S, Halstead SB. An explanation for enhanced virus plaque formation in chick embryo cells. Nature. 1980;285:504–5.
pubmed: 7402295
doi: 10.1038/285504a0
pmcid: 7402295
Halstead SB. In vivo enhancement of dengue virus infection in Rhesus monkeys by passively transferred antibody. J Infect Dis. 1979;140(4):527–33.
pubmed: 117061
doi: 10.1093/infdis/140.4.527
pmcid: 117061
Quintos FN, Lim LE, Juliano L, Reyes A, Lacson P. Hemorrhagic fever observed among children in the Philippines. Philipp J Pediatr. 1954;3(3):1–19.
Hammon WM, Rudnick A, Sather GE, Rogers KD, Morse LJ. New hemorrhagic fevers of children in the Philippines and Thailand. Trans Assoc Am Phys. 1960;73:140–55.
pubmed: 13711073
pmcid: 13711073
Halstead SB, Nimmannitya S, Yamarat C, Russell PK. Hemorrhagic fever in Thailand; recent knowledge regarding etiology. Jpn J Med Sci Biol. 1967;20:96–103.
pubmed: 5301574
pmcid: 5301574
Halstead SB, Nimmannitya S, Cohen SN. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med. 1970;42:311–28.
pubmed: 5419206
pmcid: 2591704
Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis. 2000;181(1):2–9.
pubmed: 10608744
doi: 10.1086/315215
pmcid: 10608744
Halstead SB, O’Rourke EJ. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med. 1977;146:201–17.
pubmed: 406347
pmcid: 2180729
doi: 10.1084/jem.146.1.201
Aye KS, Charngkaew K, Win N, Wai KZ, Moe K, Punyadee N, et al. Pathologic highlights of dengue hemorrhagic fever in 13 autopsy cases from Myanmar. Hum Pathol. 2014;45(6):1221–33.
pubmed: 24767772
doi: 10.1016/j.humpath.2014.01.022
pmcid: 24767772
Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science. 1988;239:476–81.
pubmed: 3277268
doi: 10.1126/science.239.4839.476
pmcid: 3277268
Halstead SB, O’Rourke EJ, Allison AC. Dengue viruses and mononuclear phagocytes. II. identity of blood and tissue leukocytes supporting in vitro infection. J Exp Med. 1977;146:218–28.
pubmed: 195000
pmcid: 2180735
doi: 10.1084/jem.146.1.218
Halstead SB. Dengue antibody-dependent enhancement: knowns and unknowns. Microbiol Spectrosc. 2014;2(6). https://doi.org/10.1128/microbiolspec.AID-0022-2014 .
Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol. 2013;158(7):1445–59.
pubmed: 23471635
doi: 10.1007/s00705-013-1645-3
pmcid: 23471635
Cohen SN, Halstead SB. Shock associated with dengue infection. I. Clinical and physiologic manifestations of dengue hemorrhagic fever in Thailand, 1964. J Pediatr. 1966;68:448–56.
pubmed: 5903315
doi: 10.1016/S0022-3476(66)80249-4
Bokisch VA, Top FH Jr, Russell PK, Dixon FJ, Muller-Eberhard HJ. The potential pathogenic role of complement in dengue hemorrhagic shock syndrome. N Engl J Med. 1973;289:996–1000.
pubmed: 4742219
doi: 10.1056/NEJM197311082891902
pmcid: 4742219
Modhiran N, Watterson D, Muller DA, Panetta AK, Sester DP, Liu L, et al. Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity. Sci Transl Med. 2015;7(304):304ra142.
pubmed: 26355031
doi: 10.1126/scitranslmed.aaa3863
Chaturvedi UC, Agarwal R, Elbishbishi EA, Mustafa AS. Cytokine cascade in dengue hemorrhagic fever: implications for pathogenesis. FEMS Immunol Med Microbiol. 2000;28(3):183–8.
doi: 10.1111/j.1574-695X.2000.tb01474.x
Rothman A. Dengue immune response: low affinity, high febrility. Nat Med. 2003;7:820–2.
Beatty PR, Puerta-Guardo H, Killingbeck SS, Glasner DR, Hopkins K, Harris E. Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination. Sci Transl Med. 2015;7(304):304ra141.
pubmed: 26355030
doi: 10.1126/scitranslmed.aaa3787
Anderson KB, Gibbons RV, Thomas SJ, Rothman AL, Nisalak A, Berkelman RL, et al. Preexisting Japanese encephalitis virus neutralizing antibodies and increased symptomatic dengue illness in a school-based cohort in Thailand. PLoS Negl Trop Dis. 2011;5(10):e1311.
pubmed: 21991398
pmcid: 3186763
doi: 10.1371/journal.pntd.0001311
Katzelnick LC, Narvaez C, Arguello S, Lopez Mercado B, Collado D, Ampie O, et al. Zika virus infection enhances future risk of severe dengue disease. Science. 2020;369(6507):1123–8.
pubmed: 32855339
pmcid: 8274975
doi: 10.1126/science.abb6143
Halstead SB, Porterfield JS, O’Rourke EJ. Enhancement of dengue virus infection in monocytes by flavivirus antisera. Am J Trop Med Hyg. 1980;29(4):638–42.
pubmed: 6157332
doi: 10.4269/ajtmh.1980.29.638
pmcid: 6157332
WHO. Dengue: guidelines for diagnosis, treatment prevention and control. WHO; 2009.
Sierra B, Triska P, Soares P, Garcia G, Perez AB, Aguirre E, et al. OSBPL10, RXRA and lipid metabolism confer African-ancestry protection against dengue haemorrhagic fever in admixed Cubans. PLoS Pathog. 2017;13(2):e1006220.
pubmed: 28241052
pmcid: 5344536
doi: 10.1371/journal.ppat.1006220
Bray M, Men R, Lai CJ. Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge. J Virol. 1996;70:4162–6.
pubmed: 8648761
pmcid: 190310
doi: 10.1128/jvi.70.6.4162-4166.1996
Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, Weltzin R, et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol. 2001;75(16):7290–304.
pubmed: 11462001
pmcid: 114964
doi: 10.1128/JVI.75.16.7290-7304.2001
Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373(13):1195–206.
pubmed: 26214039
doi: 10.1056/NEJMoa1506223
Who. Global advisory committee on vaccine safety, 15–16 June 2016. Wkly Epidemiol Rec. 2016;91(28/29):341–8.
Huang CY, Kinney RM, Livengood JA, Bolling B, Arguello JJ, Luy BE, et al. Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax). PLoS Negl Trop Dis. 2013;7(5):e2243.
pubmed: 23738026
pmcid: 3667780
doi: 10.1371/journal.pntd.0002243
Yoksan S. Short history of dengue and Mahidol dengue vaccine. South East Asian J Trop Med Pub Health. 2017;48(Supplement 1):20–32.
Vaughn DW, Hoke CH Jr, Yoksan S, LaChance R, Innis BL, Rice RM, et al. Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. Vaccine. 1996;14(4):329–36.
pubmed: 8744561
doi: 10.1016/0264-410X(95)00167-Y
Biswal S, Reynales H, Saez-Llorens X, Lopez P, Borja-Tabora C, Kosalaraksa P, et al. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N Engl J Med. 2019;381(21):2009–19.
pubmed: 31693803
doi: 10.1056/NEJMoa1903869
pmcid: 31693803
López-Medina E, Biswal S, Saez-Llorens X, Borja-Tabora C, Bravo L, Sirivichayakul C, et al. Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents two years after vaccination. J Infect Dis. 2020:jiaa761. https://doi.org/10.1093/infdis/jiaa761 .
Simmons JS, St John JH, Reynolds FHK. Experimental studies of dengue. Philipp J Sci. 1931;44:1–252.
Blanc G, Caminopetros J. Recherches experimentales sur la dengue. Ann Inst Pasteur (Paris). 1930;44(4):367–436.
Putnak R, Cassidy K, Conforti N, Lee R, Sollazzo D, Truong T, et al. Immunogenic and protective response in mice immunized with a purified, inactivated, Dengue-2 virus vaccine prototype made in fetal rhesus lung cells. Am J Trop Med Hyg. 1996;55(5):504–10.
pubmed: 8940981
doi: 10.4269/ajtmh.1996.55.504
Putnak RJ, Coller BA, Voss G, Vaughn DW, Clements D, Peters I, et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine. 2005;23(35):4442–52.
doi: 10.1016/j.vaccine.2005.03.042
Fernandez S, Thomas SJ, De La Barrera R, Im-Erbsin R, Jarman RG, Baras B, et al. An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques. Am J Trop Med Hyg. 2015;92(4):698–708.
pubmed: 25646261
pmcid: 4385761
doi: 10.4269/ajtmh.14-0268
Martinez LJ, Lin L, Blaylock JM, Lyons AG, Bauer KM, De La Barrera R, et al. Safety and immunogenicity of a dengue virus serotype-1 purified-inactivated vaccine: results of a phase 1 clinical trial. Am J Trop Med Hyg. 2015;93(3):454–60.
pubmed: 26149862
pmcid: 4559679
doi: 10.4269/ajtmh.14-0819
Diaz C, Lin L, Martinez LJ, Eckels KH, Campos M, Jarman RG, et al. Phase 1 randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults from Puerto Rico. Am J Trop Med Hyg. 2018;98(5):1435–43.
Lin L, Lyke KE, Koren M, Jarman RG, Eckels KH, Lepine E, et al. Safety and immunogenicity of an AS03(B)-adjuvanted inactivated tetravalent dengue virus vaccine administered on varying schedules to healthy U.S. adults: a phase 1/2 randomized study. Am J Trop Med Hyg. 2020;103(1):132–41.
pubmed: 32342848
pmcid: 7356407
doi: 10.4269/ajtmh.19-0738
Borges MB, Marchevsky RS, Carvalho Pereira R, da Silva Mendes Y, Almeida Mendes LG, Diniz-Mendes L, et al. Detection of post-vaccination enhanced dengue virus infection in macaques: an improved model for early assessment of dengue vaccines. PLoS Pathog. 2019;15(4):e1007721.
pubmed: 31009499
pmcid: 6497418
doi: 10.1371/journal.ppat.1007721
Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3’-untranslated region. Am J Trop Med Hyg. 2001;65:405–13.
pubmed: 11716091
doi: 10.4269/ajtmh.2001.65.405
Kirkpatrick BD, Durbin AP, Pierce KK, Carmolli MP, Tibery CM, Grier PL, et al. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J Infect Dis. 2015;212(5):702–10.
pubmed: 25801652
pmcid: 4612392
doi: 10.1093/infdis/jiv082
Kirkpatrick BD, Whitehead SS, Pierce KK, Tibery CM, Grier PL, Hynes NA, et al. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. Sci Transl Med. 2016;8(330):330ra36.
pubmed: 27089205
doi: 10.1126/scitranslmed.aaf1517
Tsai WY, Durbin A, Tsai JJ, Hsieh SC, Whitehead S, Wang WK. Complexity of neutralization antibodies against multiple dengue viral serotypes after heterotypic immunization and secondary infection revealed by in-depth analysis of cross-reactive antibodies. J Virol. 2015;89(14):7348–62.
pubmed: 25972550
pmcid: 4473561
doi: 10.1128/JVI.00273-15
Angelo MA, Grifoni A, O'Rourke PH, Sidney J, Paul S, Peters B, et al. Human CD4+ T cell responses to an attenuated tetravalent dengue vaccine parallel those induced by natural infection in magnitude, HLA restriction, and antigen specificity. J Virol. 2017;91(5).
Lopes TRR, Silva CS, Pastor AF, Silva Junior JVJ. Dengue in Brazil in 2017: what happened? Rev Inst Med Trop Sao Paulo. 2018;60:e43.
pubmed: 30133603
pmcid: 6103327
doi: 10.1590/s1678-9946201860043
Buser F. Side reaction to measles vaccination suggesting the arthus phenomenon. N Engl J Med. 1967;277:250–1.
pubmed: 4226465
doi: 10.1056/NEJM196708032770507
Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock K, Jensen K, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89:422–34.
pubmed: 4305198
doi: 10.1093/oxfordjournals.aje.a120955
Polack FP, Auwaerter PG, Lee SH, Nousari HC, Valsamakis A, Leiferman KM, et al. Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat Med. 1999;5(6):629–34.
pubmed: 10371500
doi: 10.1038/9473
Polack FP, Teng MN, Collins PL, Prince GA, Exner M, Regele H, et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med. 2002;196(6):859–65.
pubmed: 12235218
pmcid: 2194058
doi: 10.1084/jem.20020781
Polack FP. Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple. Pediatr Res. 2007;62(1):111–5.
pubmed: 17515829
doi: 10.1203/PDR.0b013e3180686ce0
Acosta PL, Caballero MT, Polack FP. Brief history and characterization of enhanced respiratory syncytial virus disease. Clin Vaccine Immunol. 2015;23(3):189–95.
pubmed: 26677198
doi: 10.1128/CVI.00609-15
pmcid: 26677198
Polack FP, Lydy SL, Lee SH, Rota PA, Bellini WJ, Adams RJ, et al. Poor immune responses of newborn rhesus macaques to measles virus DNA vaccines expressing the hemagglutinin and fusion glycoproteins. Clin Vaccine Immunol. 2013;20(2):205–10.
pubmed: 23239799
pmcid: 3571263
doi: 10.1128/CVI.00394-12
Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med. 2009;15(1):34–41.
pubmed: 19079256
doi: 10.1038/nm.1894
Ponnuraj EM, Springer J, Hayward AR, Wilson H, Simoes EA. Antibody-dependent enhancement, a possible mechanism in augmented pulmonary disease of respiratory syncytial virus in the Bonnet monkey model. J Infect Dis. 2003;187(8):1257–63.
pubmed: 12696005
doi: 10.1086/374604
Gimenez HB, Chisholm S, Dornan J, Cash P. Neutralizing and enhancing activities of human respiratory syncytial virus-specific antibodies. Clin Diagn Lab Immunol. 1996;3(3):280–6.
pubmed: 8705669
pmcid: 170331
doi: 10.1128/cdli.3.3.280-286.1996
Anderson CF, Mosser DM. Cutting edge: biasing immune responses by directing antigen to macrophage Fc gamma receptors. J Immunol. 2002;168(8):3697–701.
pubmed: 11937518
doi: 10.4049/jimmunol.168.8.3697
Moghaddam A, Olszewska W, Wang B, Tregoning JS, Helson R, Sattentau QJ, et al. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med. 2006;12(8):905–7.
pubmed: 16862151
doi: 10.1038/nm1456
Olszewska W, Suezer Y, Sutter G, Openshaw PJ. Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins. Vaccine. 2004;23(2):215–21.
pubmed: 15531040
doi: 10.1016/j.vaccine.2004.05.015
Johnson TR, Rao S, Seder RA, Chen M, Graham BS. TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity. Vaccine. 2009;27(23):3045–52.
pubmed: 19428918
pmcid: 2680782
doi: 10.1016/j.vaccine.2009.03.026
Murphy BR, Walsh EE. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol. 1988;26(8):1595–7.
pubmed: 2459154
pmcid: 266671
doi: 10.1128/jcm.26.8.1595-1597.1988
Polack FP, Hoffman SJ, Crujeiras G, Griffin DE. A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat Med. 2003;9(9):1209–13.
pubmed: 12925847
doi: 10.1038/nm918
pmcid: 12925847
de Swart RL, van den Hoogen BG, Kuiken T, Herfst S, van Amerongen G, Yuksel S, et al. Immunization of macaques with formalin-inactivated human metapneumovirus induces hypersensitivity to hMPV infection. Vaccine. 2007;25(51):8518–28.
pubmed: 17996988
doi: 10.1016/j.vaccine.2007.10.022
pmcid: 17996988
Tregoning JS, Yamaguchi Y, Harker J, Wang B, Openshaw PJ. The role of T cells in the enhancement of respiratory syncytial virus infection severity during adult reinfection of neonatally sensitized mice. J Virol. 2008;82(8):4115–24.
pubmed: 18272579
pmcid: 2293007
doi: 10.1128/JVI.02313-07
Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS ONE. 2012;7(4):e35421.
pubmed: 22536382
pmcid: 3335060
doi: 10.1371/journal.pone.0035421
Bolles M, Donaldson E, Baric R. SARS-CoV and emergent coronaviruses: viral determinants of interspecies transmission. Curr Opin Virol. 2011;1(6):624–34.
pubmed: 22180768
pmcid: 3237677
doi: 10.1016/j.coviro.2011.10.012
Yasui F, Kai C, Kitabatake M, Inoue S, Yoneda M, Yokochi S, et al. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J Immunol. 2008;181(9):6337–48.
pubmed: 18941225
doi: 10.4049/jimmunol.181.9.6337
pmcid: 18941225
Weingartl H, Czub M, Czub S, Neufeld J, Marszal P, Gren J, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol. 2004;78(22):12672–6.
pubmed: 15507655
pmcid: 525089
doi: 10.1128/JVI.78.22.12672-12676.2004
Wang Q, Zhang L, Kuwahara K, Li L, Liu Z, Li T, et al. Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates. ACS Infect Dis. 2016;2(5):361–76.
pubmed: 27627203
pmcid: 7075522
doi: 10.1021/acsinfecdis.6b00006
Horstmann DM, Liebhaber H, Le Bouvier GL, Rosenberg DA, Halstead SB. Rubella: reinfection of vaccinated and naturally immune persons exposed in an epidemic. N Engl J Med. 1970;283(15):771–8.
pubmed: 5456233
doi: 10.1056/NEJM197010082831501
pmcid: 5456233
Vennema H, DeGroot RJ, Harbour DA, Dalderup M, Gruffydd-Jones T, Horzinek MC, Spaan WJM. Early death after feline infectious peritonitis challenge due to recombinant vaccinia virus immunization. J Virol. 1990;64:1407–9.
pubmed: 2154621
pmcid: 249267
doi: 10.1128/jvi.64.3.1407-1409.1990
Vennema H, Poland A, Foley J, Pedersen NC. Feline infectious peritonitis viruses arise by mutation from endemic feline enteric coronaviruses. Virology. 1998;243(1):150–7.
pubmed: 9527924
doi: 10.1006/viro.1998.9045
pmcid: 9527924
Porter DDL, AE, Porter HG. Aleutian disease of mink. Adv Immunol. 1980;29:261–86.
Zhu HW, Xing XM, Wen YJ. Eenie, Meenie, Miney, Moe, who is responsible for the antibody-dependent enhancement of Aleutian mink disease parvovirus infection?. Chin J Virol. 2014;30(4):450–5.
Porter DD, Larsen AE, Porter HG. The pathogenesis of Aleutian disease of mink. I. In vivo viral replication and the host antibody response to viral antigen. J Exp Med. 1969;130:575–93.
pubmed: 4979953
pmcid: 2138710
doi: 10.1084/jem.130.3.575
Porter AD, Larsen AE, Porter HG. The pathogenesis of Aleutian disease of mink. II. Enhancement of tissue lesions following the administration of a killed virus vaccine or passive antibody. J Immunol. 1972;109:1–7.
pubmed: 4556259
pmcid: 4556259
Kanno H, Wohlinbarger JB, Bloom ME. Aleutian mink disease parvovirus infection of mink macrophages and human macrophage cell line *937: demonstration of antibody-dependent enhancement of infection. J Virol. 1993;67:7017–24.
pubmed: 8230426
pmcid: 238162
doi: 10.1128/jvi.67.12.7017-7024.1993
Plagemann PG. Porcine reproductive and respiratory syndrome virus: origin hypothesis. Emerg Infect Dis. 2003;9(8):903–8.
pubmed: 12967485
pmcid: 3020618
doi: 10.3201/eid0908.030232
Gómez-Laguna J, Salguero FJ, Pallarés FJ, Carrasco L. Immunopathogenesis of porcine reproductive and respiratory syndrome in the respiratory tract of pigs. Vet J. 2013;195(2):148–55.
pubmed: 23265866
doi: 10.1016/j.tvjl.2012.11.012
pmcid: 23265866
Yoon KJ, Wu LL, Zimmerman JJ, Hill HT, Platt KB. Antibody-dependent enhancement (ADE) of porcine reproductive and respiratory syndrome virus (PRRSV) infection in pigs. Viral Immunol. 1996;9(1):51–63.
pubmed: 8733920
doi: 10.1089/vim.1996.9.51
pmcid: 8733920
Wan B, Chen X, Li Y, Pang M, Chen H, Nie X, et al. Porcine FcγRIIb mediated PRRSV ADE infection through inhibiting IFN-β by cytoplasmic inhibitory signal transduction. Int J Biol Macromol. 2019;1(138):198–206.
doi: 10.1016/j.ijbiomac.2019.07.005
Iseki H, Kawashima K, Takagi M, Shibahara T, Mase M. Studies on heterologous protection between Japanese type 1 and type 2 porcine reproductive and respiratory syndrome virus isolates. J Vet Med Sci. 2020;82(7):935–42.
pubmed: 32448816
pmcid: 7399305
doi: 10.1292/jvms.20-0122
Zhou L, Ge X, Yang H. Porcine reproductive and respiratory syndrome modified live virus vaccine: a "Leaky" vaccine with debatable efficacy and safety. Vaccines. 2021;9(4):362. https://doi.org/10.3390/vaccines9040362 .
Kim JK, Seiler P, Forrest HL, Khalenkov AM, Franks J, Kumar M, et al. Pathogenicity and vaccine efficacy of different clades of Asian H5N1 avian influenza A viruses in domestic ducks. J Virol. 2008;82(22):11374–82.
pubmed: 18786988
pmcid: 2573247
doi: 10.1128/JVI.01176-08
Mancera Gracia JC, Pearce DS, Masic A, Balasch M. Influenza A virus in swine: epidemiology, challenges and vaccination strategies. Front Vet Sci. 2020;7:647.
pubmed: 33195504
pmcid: 7536279
doi: 10.3389/fvets.2020.00647
Chan CYY, Low JZH, Gan ES, Ong EZ, Zhang SL, Tan HC, et al. Antibody-dependent dengue virus entry modulates cell intrinsic responses for enhanced infection. mSphere. 2019;4(5):e.00528-19. https://doi.org/10.1128/mSphere.00528-19 .
Webster RG, Askonas BA. Cross-protection and cross reactive cytotoxic T cells induced by influenza virus vaccines in mice. Eur J Immunol. 1980;10:396–401.
pubmed: 6967815
doi: 10.1002/eji.1830100515
pmcid: 6967815
Chanock RM, Parrott RH, Kapakian AZ. Possible role of immunological factors in pathogenesis of RS virus in lower respiratory tract disease. Perspect Virol. 1968;6:125–35.
King AA, Sands JJ, Porterfield JS. Antibody-mediated enhancement of rabies virus infection in a mouse macrophage cell line (P388D1). J Gen Virol. 1984;65:1091–3.
pubmed: 6726187
doi: 10.1099/0022-1317-65-6-1091
pmcid: 6726187
Prabhakar BS, Nathanson N. Acute rabies deaths mediated by antibody. Nature. 1981;290:590–5991.
pubmed: 6971412
doi: 10.1038/290590a0
pmcid: 6971412
Tirado SM, Yoon KJ. Antibody-dependent enhancement of virus infection and disease. Viral Immunol. 2003;16(1):69–86.
pubmed: 12725690
doi: 10.1089/088282403763635465
pmcid: 12725690
Burke DS. Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk? Perspect Biol Med. 1992;35:511–30.
pubmed: 1513680
doi: 10.1353/pbm.1992.0048
pmcid: 1513680
Mdurvwa EG, Ogunbiyi PO, Gakou HS, Reddy PG. Pathogenic mechanisms of caprine arthritis-encephalitis virus. Vet Res Commun. 1994;18(6):483–90.
pubmed: 7701786
doi: 10.1007/BF01839425
Mealey RH, Leib SR, Littke MH, Wagner B, Horohov DW, McGuire TC. Viral load and clinical disease enhancement associated with a lentivirus cytotoxic T lymphocyte vaccine regimen. Vaccine. 2009;27(18):2453–68.
pubmed: 19368787
pmcid: 2773546
doi: 10.1016/j.vaccine.2009.02.048